Brought to you by 
Biohaven licenses BHV5000 from AstraZeneca for up to $220mm
24 Jul 2017
Executive Summary
Biohaven Pharmaceuticals Holding Co. Ltd. in-licensed exclusive, worldwide development, manufacturing, and commercialization rights to AstraZeneca PLC's discontinued intravenous lanicemine (formerly AZD6765) and certain related patent rights and know-how to develop an oral prodrug it will call BHV5000.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biohaven licenses BHV5000 from AstraZeneca for up to $220mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice